139 related articles for article (PubMed ID: 37805444)
21. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
22. Pedigree and BRCA gene analysis in breast cancer patients to identify hereditary breast and ovarian cancer syndrome to prevent morbidity and mortality of disease in Indian population.
Darooei M; Poornima S; Salma BU; Iyer GR; Pujar AN; Annapurna S; Shah A; Maddali S; Hasan Q
Tumour Biol; 2017 Feb; 39(2):1010428317694303. PubMed ID: 28231738
[TBL] [Abstract][Full Text] [Related]
23. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J; Giannakeas V; Karlan B; Lubinski J; Gronwald J; Rosen B; McLaughlin J; Risch H; Sun P; Foulkes WD; Neuhausen SL; Kotsopoulos J; Narod SA;
Gynecol Oncol; 2017 May; 145(2):346-351. PubMed ID: 28314588
[TBL] [Abstract][Full Text] [Related]
24. [Prophylactic surgery of mammary and ovarian carcinoma].
Lux MP; Bani MR; Fasching PA; Beckmann MW
Chirurg; 2005 Dec; 76(12):1145-54. PubMed ID: 16237564
[TBL] [Abstract][Full Text] [Related]
25. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for lymph node metastasis of ovarian, fallopian tube and primary peritoneal cancer in hereditary breast and ovarian cancer syndrome.
Mitamura T; Sekine M; Arai M; Shibata Y; Kato M; Yokoyama S; Yamashita H; Watari H; Yabe I; Nomura H; Enomoto T; Nakamura S;
Jpn J Clin Oncol; 2020 Dec; 50(12):1380-1385. PubMed ID: 32676635
[TBL] [Abstract][Full Text] [Related]
27. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers.
Singh K; Lester J; Karlan B; Bresee C; Geva T; Gordon O
Am J Obstet Gynecol; 2013 Apr; 208(4):329.e1-6. PubMed ID: 23333547
[TBL] [Abstract][Full Text] [Related]
28. Breast and ovarian cancer risk perception after prophylactic salpingo-oophorectomy due to an inherited mutation in the BRCA1 or BRCA2 gene.
Finch A; Metcalfe K; Lui J; Springate C; Demsky R; Armel S; Rosen B; Murphy J; Elit L; Sun P; Narod S
Clin Genet; 2009 Mar; 75(3):220-4. PubMed ID: 19263514
[TBL] [Abstract][Full Text] [Related]
29. BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.
Lerman C; Narod S; Schulman K; Hughes C; Gomez-Caminero A; Bonney G; Gold K; Trock B; Main D; Lynch J; Fulmore C; Snyder C; Lemon SJ; Conway T; Tonin P; Lenoir G; Lynch H
JAMA; 1996 Jun; 275(24):1885-92. PubMed ID: 8648868
[TBL] [Abstract][Full Text] [Related]
30. Risk management options elected by women after testing positive for a BRCA mutation.
Garcia C; Wendt J; Lyon L; Jones J; Littell RD; Armstrong MA; Raine-Bennett T; Powell CB
Gynecol Oncol; 2014 Feb; 132(2):428-33. PubMed ID: 24355485
[TBL] [Abstract][Full Text] [Related]
31. Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.
Roukos DH; Briasoulis E
Nat Clin Pract Oncol; 2007 Oct; 4(10):578-90. PubMed ID: 17898808
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Incidental Fallopian Tube High-Grade Serous Carcinoma and Serous Tubal Intraepithelial Carcinoma in Women at Low Risk of Hereditary Breast and Ovarian Cancer.
Chay WY; McCluggage WG; Lee CH; Köbel M; Irving J; Millar J; Gilks CB; Tinker AV
Int J Gynecol Cancer; 2016 Mar; 26(3):431-6. PubMed ID: 26807643
[TBL] [Abstract][Full Text] [Related]
33. Summaries for patients. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: U.S. Preventive Services Task Force recommendations.
Ann Intern Med; 2005 Sep; 143(5):I47. PubMed ID: 16144889
[No Abstract] [Full Text] [Related]
34. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening.
Paluch-Shimon S; Cardoso F; Sessa C; Balmana J; Cardoso MJ; Gilbert F; Senkus E;
Ann Oncol; 2016 Sep; 27(suppl 5):v103-v110. PubMed ID: 27664246
[No Abstract] [Full Text] [Related]
35. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study.
de Juan I; Palanca S; Domenech A; Feliubadaló L; Segura Á; Osorio A; Chirivella I; de la Hoya M; Sánchez AB; Infante M; Tena I; Díez O; Garcia-Casado Z; Vega A; Teulé À; Barroso A; Pérez P; Durán M; Carrasco E; Juan-Fita MJ; Murria R; Llop M; Barragan E; Izquierdo Á; Benítez J; Caldés T; Salas D; Bolufer P
Fam Cancer; 2015 Dec; 14(4):505-13. PubMed ID: 26026974
[TBL] [Abstract][Full Text] [Related]
36. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.
Nelson HD; Pappas M; Zakher B; Mitchell JP; Okinaka-Hu L; Fu R
Ann Intern Med; 2014 Feb; 160(4):255-66. PubMed ID: 24366442
[TBL] [Abstract][Full Text] [Related]
37. Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.
Tong A; Kelly S; Nusbaum R; Graves K; Peshkin BN; Valdimarsdottir HB; Wood M; McKinnon W; Garber J; McCormick SR; Jandorf L; Schwartz MD
Psychooncology; 2015 Jan; 24(1):33-9. PubMed ID: 24839250
[TBL] [Abstract][Full Text] [Related]
38. BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
Li A; Xie R; Zhi Q; Deng Y; Wu Y; Li W; Yang L; Jiao Z; Luo J; Zi Y; Sun G; Zhang J; Shi Y; Liu J
Gynecol Oncol; 2018 Oct; 151(1):145-152. PubMed ID: 30078507
[TBL] [Abstract][Full Text] [Related]
39. Provider Discussions of Genetic Tests With U.S. Women at Risk for a BRCA Mutation.
Hull LE; Haas JS; Simon SR
Am J Prev Med; 2018 Feb; 54(2):221-228. PubMed ID: 29241717
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic surgery in hereditary breast/ovarian cancer syndrome.
Levine DA; Gemignani ML
Oncology (Williston Park); 2003 Jul; 17(7):932-41; discussion 946-8, 950-2. PubMed ID: 12886864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
